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756The therapeutic effect of vascular endothelial
growth factor gene- or heme oxygenase-1
gene-modiﬁed endothelial progenitor cells on
neovascularization of rat hindlimb ischemia model
Jianting Long, MD, PhD,a Sanming Wang, MD, PhD,b Yuanqi Zhang, MD, PhD,a
Xiangxia Liu, MD, PhD,c Hui Zhang, MD, PhD,d and Shenming Wang, MD, PhD,a Guangzhou, China
Objective: To explore the therapeutic potential of endothelial progenitor cells (EPCs) transfected with vascular endothelial
growth factor A (VEGFA) and heme oxygenase-1 (HO-1) on rat hindlimb ischemia model.
Methods: Eukaryotic expression vectors encoding VEGFA or HO-1 were constructed and introduced into EPCs isolated
from rat bone marrow. In total, 150 Sprague Dawley rat hindlimb ischemia models were established and randomized into
ﬁve groups which were injected via tail vein with phosphate-buffered saline (PBS), nontransfected EPCs, VEGFA-
modiﬁed EPCs, HO-1-modiﬁed EPCs, and both VEGFA- and HO-1-modiﬁed EPCs, respectively. The microvessel
density, the expressions of VEGFA and HO-1 in the ischemic limbs, the recovery of blood ﬂow as evaluated by laser-
Doppler perfusion imaging, and the rate of limb salvage were compared among different groups.
Results: Transplantation of both VEGFA- andHO-1-modiﬁed EPCs in recipient rats signiﬁcantly increased themicrovessel
density (expressed as capillaries/m2 at day 21 after operation, group vascular endothelial growth factor (VEGF)DHO-1,
3576 14.1; group VEGF, 253.76 9.9; group HO-1, 255.56 12.5; group EPC, 210.76 10.3; group PBS, 144.36 9.3;
P < .001), the expressions of VEGFA and HO-1 in ischemic tissue, the recovery of blood ﬂow (at day 21, VEGFDHO-1
group, 85.4 6 17.8%; VEGF group, 51.2 6 13.2%; HO-1 group, 50.4 6 12.9%; EPC group, 39.9 6 8.5%; PBS group,
28.3 6 7.8%; P < .001), and the rate of limb salvage (VEGFDHO-1 group, 94.4%; VEGF group or HO-1 group, 63.6%;
EPC group, 50.0%; PBS group, 11.1%), compared with transplantation of either VEGFA- or HO-1-modiﬁed EPCs alone,
or of nontransfected EPCs, or PBS injection. The order of therapeutic effectiveness on ischemic limbs was VEGFA- D
HO-1-modifed EPC > either VEGFA- or HO-1-modiﬁed EPC alone > nontransfected EPC > PBS.
Conclusions: VEGFA-modiﬁed EPC and HO-1-modiﬁed EPC synergized with each other in promoting angiogenesis in
ischemic limbs of rat hindlimb ischemia model. In addition to VEGF, the introduction of HO-1 in EPC-based trans-
plantation may serve as a novel and useful therapeutic strategy for ischemic disease of lower extremity. (J Vasc Surg
2013;58:756-65.)
Clinical Relevance: Genetically modiﬁed endothelial progenitor cell (EPC) is useful in designing strategies to achieve dual
purposes in treating peripheral arterial disease: targeted delivery of therapeutic genes using EPC as vehicle, and enhance-
ment on the angiogenic properties of EPC by the expression of therapeutic genes. Heme oxygenase-1 (HO-1) has been
shown to play an important role in ischemic angiogenesis, aside from its role as an antioxidant protein. We have shown for
the ﬁrst time that vascular endothelial growth factor A-modiﬁed EPC andHO-1-modiﬁed EPC synergized with each other
in promoting angiogenesis in rat hindlimb ischemia model. These ﬁndings provide further evidence of the importance of
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://dx.doi.org/10.1016/j.jvs.2012.11.096The prevalence of peripheral arterial disease (PAD)
affecting the lower extremities rises in line with an ageing
population in China. Patients with continued progression
of PAD will experience the end-stage critical limb ischemia
(CLI) resulting in amputation of the affected limb and
increased mortality.1 Revascularization can be achieved
either by endovascular interventions or open surgery
combined with anticoagulation and antiplatelet agents.
Unfortunately, a considerable proportion of patients are
not eligible for these revascularization procedures because
of the widespread nature, the distal location of the obstruc-
tions, or the presence of comorbidities.2 For these patients,
noninvasive revascularization strategies, mainly single
gene/protein-based or cell-based, have been developed.
Recently, a number of double-blind, randomized phase
I/II trials have veriﬁed the safety and efﬁcacy of local injec-
tion with bone marrow (BM) aspirate concentrate3 or BM
JOURNAL OF VASCULAR SURGERY
Volume 58, Number 3 Long et al 757derived cells with4 or without5 in vitro expansion in
patients with “no option” CLI. Though not powered to
show statistical signiﬁcance, these studies demonstrate
favorable outcome for cell therapy vs control in amputation
free survival, ankle brachial index, wound healing,
improved Rutherford classiﬁcation, and quality of life, indi-
cating that autologous BM cell-based therapy is a safe and
effective strategy to promote limb salvage in CLI patients.
However, the exact mechanisms of action for these cells (a
mixture of mesenchymal and hematopoietic progenitor
cells and other cell types in BM) in treating CLI are not
well established. It is unclear whether these cells are directly
involved in angiogenesis or just providing cytokines. The
adoption of a more puriﬁed cell population may be a better
choice to illustrate part of the mechanism.
Endothelial progenitor cells (EPCs) are not only
involved in embryonic vascularization, but also played an
important role in adult organism angiogenesis.6 Reduced
circulating EPC number or function indicates an impaired
endothelial repair capacity resulting in increased risk of
vascular disease.7,8 Infusion of ex vivo expanded EPC
derived from BM or peripheral blood was shown to
augment capillary density and neovascularization of
ischemic tissue in animal models.9 Therefore, EPC may
become a promising cell type to treat limb ischemia.10
The role of vascular endothelial growth factor (VEGF)
in treating ischemic diseases was documented two decades
ago. Isner and Losordo performed substantial preclinical
studies on the safety and efﬁcacy of direct intra-arterial or
intramuscular transfer of naked DNA encoding human
VEGF in treating PAD in animal models and in human
subjects. Their pioneering work demonstrated that VEGF
gene transfer could increase circulating EPC, augment
angiogenesis after ischemia, and accelerate endothelial
recovery after injury, providing a solid basis for further
research of therapeutic angiogenesis using VEGF gene-
based strategies.11,12
In recent years, the important role of heme oxygenase-
1 (HO-1) in postnatal angiogenesis was gradually recog-
nized.13 HO-1 is an enzyme that catalyzes the ﬁrst,
rate-limiting step in degradation of heme into carbon
monoxide (CO), ferrous iron, and biliverdin. Known to
have cytoprotective, proangiogenic, and antiapoptotic
properties, these three smaller compounds, together with
HO-1 itself, are claimed to be the second, after gluta-
thione, most important part of the anti-oxidative protec-
tion system.13,14 Recent data provided powerful evidence
for the involvement of HO-1 in therapeutic angiogenesis,
making HO-1-based gene or cell therapy a promising
strategy to treat ischemic diseases.15 Furthermore, HO-1
was reported to form a positive feed-back loop with
VEGF.16 Grochot-Przeczek et al recently discovered that
HO-1 functioned both upstream and downstream of
VEGF, inducing its expression and being required for the
proper response of EPC to VEGF stimulation.17 We
hypothesize that the application of both HO-1- and
VEGF-based therapies to ischemic disease model at the
same time may lead to more effective angiogenesis.In our previous study, we reported that local application
of stromal-derived factor-1a synergized with vascular
endothelial growth factor A (VEGFA)-modiﬁed EPC in
therapeutic angiogenesis by enhancing EPC migration,
reducing EPC apoptosis, and increasing capillary density
and blood ﬂow recovery.18 In this study, we transplant EPC
overexpressing either HO-1 or VEGFA into rat hindlimb
ischemia model and investigate whether HO-1 and VEGFA
can synergize with each other in facilitating angiogenesis.
METHODS
Mouse EPC isolation and culture. Male Sprague-
Dawley rats were provided by Laboratory Animal Centre
of Sun Yat-sen University. All researches involving animals
were approved by the Institutional Animal Care and Use
Committee of Sun Yat-Sen University. Bone marrow
mononuclear cells were isolated from Sprague-Dawley rat
bones as described previously,19 cultured in endothelial cell
basal medium-2 (Clonetics; Lonza, Walkersville, Md)
supplemented with 20% fetal bovine serum, human VEGF,
ﬁbroblast growth factor 2, epidermal growth factor,
insulin-like growth factor-1, ascorbic acid, and antibiotics.
All growth factors were purchased from Peprotech, Rocky
Hill, NJ. After 4 days of culture, nonadherent cells were
removed, fresh medium was applied, and the culture was
maintained through day 7.20 Cells at passage 3 (P3) were
cultured for later experiments.
Construction of VEGF and HO-1 expression
vectors and gene transfer into EPC. VEGFA and HO-1
genes were ampliﬁed by polymerase chain reaction using
DNAs extracted from Sprague-Dawley rat aorta and spleen
as templates, respectively. Primers for VEGFA (NM-
031836): up-stream: 50-GACGGATCCATGAACTTTC
TGCTCTCTTGGGTGC-30, down-stream: 50-TGAAAGC
TTTCACCGCCTTGGCTTGTCAC-30; and HO-1 (NM-
012580): up-stream: 50-CGGGATCCATGGAGCGCCCA
CAGCTCGAC-30, down-stream: 50-CCCAAGCTTTTAC
ATGGCATAAATTCCCAC-30 were used. The polymerase
chain reaction products were digested with bamHI and
hindIII (Invitrogen, Carlsbad, Calif), and cloned into
a pCMV-Tag 2B expression vector that was provided by Dr
AnlongXu inLife ScienceCollege of SunYat-senUniversity.
pCMV-Tag 2B/VEGFA or pCMV-Tag 2B/HO-1 were
transfected into the EPCs using lipofectamine 2000 (Invi-
trogen). The pEGFP (Clontech, Mountain View, Calif) was
cotransfected as an internal control for transfection efﬁ-
ciency. Western blotting detections of VEGF-R2, VEGF,
and HO-1 proteins were performed as described in the
Supplementary Methods section (online only).
RNA extraction and real-time quantitative polymerase
chain reaction. A detailed description is available in the
Supplementary Methods section (online only). The fol-
lowing oligonucleotide primers were used: rat b-actin:
sense 50-CCTGTATGCCTCTGGTCGTA-30, anti-sense
50-CCATCTCTTGCTCGAAGTCT-3021; rat VEGF-R2:
sense, 50-TAGCACGACAGAGACTGTGAGG-30; anti-
sense, 50-TGAGGTGAGAGAGATGGGTAGG-3022; and
rat HO-1: sense 50-CGTGCAGAGAATTCTGAGTTC-30,
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VEGFA: sense 50-CGTCTACCAGCGCAGCTATTG-30,
anti-sense 50-CACACAGGACGGCTTGAAGAT-30.23
Quantiﬁcation was processed using Q-Gene software
(free web access to this program is available at http://
www.biotechniques.com/softlib/qgene.html).24
Identiﬁcation of rat BM-derived EPC. P3
EPCs were subjected to 1,1-dioctadecyl-3,3,30,30-
tetramethylindocarbocyanine-labeled acetylated low-density
lipoprotein (Dil-Ac-LDL) and ﬂuorescein isothiocyanate-
labeled lectin from Ulex europaeus agglutinin I (FITC-
UEA-1-lectin) double staining25 and ﬂow cytometry analysis
for CD34 and CD133 surface markers. EPCs crawling
microscopic slides of logarithmic growth were subjected to
immunohistochemical (IHC) staining for CD34, CD133,
and Von Willebrand factor (vWF). A detailed description is
available in the SupplementaryMethods section (onlineonly).
EPC transplantation animal model. Male Sprague-
Dawley rats, 8-9 weeks’ old, weighing 180-200 g, were
intraperitoneally anesthetized with sodium pentobarbital
(160 mg/kg) for operative resection of the femoral artery
in one of the hindlimbs, as described brieﬂy in the
Supplementary Methods section (online only). In total,
150 animals were randomized into ﬁve groups according to
transplantation regime received through tail vein after
surgery: phosphate-buffered saline (PBS) injection, trans-
plantation of nontransfected EPC (EPC), pCMV-Tag
2B/VEGFA-transfected EPC (VEGF), pCMV-Tag 2B/
HO-1-transfected EPC (HO-1), and both pCMV-Tag
2B/VEGFA and pCMV-Tag 2B/HO-1-transfected EPC
(VEGFþHO-1). Within each group, six animals were
euthanized at days 7 and 14 to obtain ischemic tissue for
quantitative polymerase chain reaction (Q-PCR), Western
blotting, and microvessel density (MVD) measurement;
the remaining 18 animals were scanned with laser Doppler
imager (LDPI) and evaluated macroscopically for ischemic
damage at days 7, 14, and 21. At day 21, six out of the 18
rats were euthanized for MVD measurement after LDPI
scanning. Immediately after the operation, each animal was
injected with 0.2 mL PBS in group PBS, 0.2 mL EPC cell
suspension (5  105 cells) in group EPC, 0.2 mL VEGFA-
modiﬁed EPC (2.5  105 cells) in group VEGF, 0.2 mL
HO-1-modiﬁed EPC (2.5  105 cells) in group HO-1,
and 0.2 mL cell suspension containing both VEGFA- and
HO-1-modiﬁed EPC (2.5  105 cells per gene) in group
VEGFþHO-1. Indicators such as expressions of VEGFA,
HO-1, or MVD, perfusion, and salvage rate of ischemic
limb were tested and compared among different groups.
In vitro labeling of EPCs with BrdU and IHC
staining of BrdU in ischemic tissue. A measurement of
10 mL of the 1 mM BrdU (550891; BD Pharmingen,
San Diego, Calif) working solution was added directly to
each mL of tissue culture media, with cell density of 1 
106/mL. After incubation for 48 hours, cells were har-
vested and adjusted to a density of 2.5  106/mL before
injecting into the animals. Animals were sacriﬁced at days 7
and 14 after the operation. Parafﬁn-embedded sections of
rat muscle tissue taken from the ischemic area weresubjected to IHC staining for BrdU using BrdU in situ
detection kit (551321, BD Pharmingen).
MVD measurement. Determination of the MVD was
performed as previously described.26 Brieﬂy, after IHC
staining for vWF in ischemic tissue specimens, each slide was
ﬁrst scanned under a low power objective lens to determine
“hot spots” deﬁned as areas with the maximum number of
microvessels.The slideswere thenexaminedat400.Areasof
stainingwithnodiscretebreakswere counted as a single vessel.
Data were expressed as mean 6 standard deviation/mm2 of
10 randomly selected nonoverlapping high-power ﬁelds.
Laser Doppler perfusion imaging assessment and
ischemic damage assessment. LDPI (Lisca AB, Linkö-
ping, Sweden) was used to record blood ﬂow changes on
days 7, 14, and 21 after surgery, as previously described.18
Brieﬂy, the animal was put in dorsal position after intra-
peritoneal anesthesia with its hindlimb slightly ﬁxed and
excess hairs removed before imaging. Room temperature
was stabilized at 25C. To account for variables including
light and temperature, calculated perfusion was expressed
as a ratio of surgical to nonsurgical limb. The degree of
ischemic damage on the affected limb was evaluated once
every 3 days macroscopically.
Statistical analysis. All results were expressed as
mean6 standard deviation. Statistical signiﬁcance was eval-
uated using the paired t-test for comparisons between two
means. Comparisons between multiple groups were done
using ANOVA. All statistical analyses were performed
using SPSS v. 17.0 (SPSS Inc, Chicago, Ill). A P value of
.05 was considered statistically signiﬁcant.
RESULTS
Identiﬁcation of EPC cultured in vitro
Morphologic changes of EPC under microscope.
Putative EPCs initially isolated (passage 1, P1) were small,
round, and undistinguishable from blood cells. Some of the
cells presented spindle shape with short protrusions at day
5, but did not display a uniform morphology. P2 cells were
predominant in adhesive growth. A considerable propor-
tion of cells changed to spindle shape with a tendency to
form cluster or colony. P3 cells displayed uniformly
spindle-shaped with long protrusions and a tendency to
form lines (Supplementary Fig 1, online only).
IHC staining of adherent cells. CD133 and CD34
antigens are shared by both embryonic EPCs and hemato-
poietic stem cells. vWF is a multifunctional hemostatic
glycoprotein derived from endothelial cells. Therefore,
testing the expressions of these three markers helps to
identify EPCs derived from BM. The expressions of
CD133, CD34, and vWF were found mainly in the cyto-
plasm, as indicated by yellow or brown color. As shown in
Fig 1, P3 cells appeared moderately positive for CD133
(Fig 1, A2) whereas weakly positive for both CD34 (Fig 1,
A3) and vWF (Fig 1, A4) in the absence of VEGF
induction. After three generations of human VEGF
induction, the expressions of CD34 and vWF dramatically
increased (Fig 1, B3 and B4).
Fig 1. Immunohistochemical staining of endothelial progenitor cells (EPCs). P3 EPCs crawling microscopic slides
were prepared for immunohistochemical staining for CD133 (A2 and B2), CD34 (A3 and B3), and Von Willebrand
factor (vWF) (A4 and B4). The expressions of CD34 and vWF dramatically increased in P3 cells with human vascular
endothelial growth factor (VEGF) induction (B3 and B4), compared with P3 cells without VEGF induction (A2-A4).
Representative images of three independent experiments were shown.
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EPCs. As shown in Fig 2, A, the percentage of cells
positive for CD133 in P3 was (97.3% 6 1.5%), whereas
that of CD34 in P3 was (55.5% 6 3.2%). After induction
of VEGF, there was no signiﬁcant change in the
percentage of cells positive for CD133 (91.4% 6 1.2%),
whereas the percentage of CD34þ cells increased to
(78.6% 6 4.2%) (P < .01).
Dil-Ac-LDL and UEA-1-lectin double-staining
detection of EPCs. The increased metabolism of
acetylated low-density lipoprotein (Ac-LDL) in endothe-
lial cells and the cytoplasmic afﬁnity of Ulex europaeus
agglutinin I (UEA-I) for capillary endothelium were put
in good use to identify epithelial lineage differentiated from
BM progenitor cells. In total, 20.4% 6 3.8% of P3 cells
were positive for both Dil-Ac-LDL (red) and UEA-1-lectin
(green) without the induction of VEGF (image not
shown). The double positive cells increased to 70.2% 6
5.1% after induction by VEGF (Fig 2, B).
Expression of VEGF-R2 in EPCs. Numerous studies
reported that VEGF-R2 was one of the most important
markers for the epithelial lineage.6 As shown in Fig 2, C,
VEGF-R2 messenger (mRNA) expression in P3 cells with
VEGF induction was roughly two times as that in cells
without induction (P < .01). Western blotting analysis also
conﬁrmed that VEGF induction increased the protein
expression of VEGF-R2 in P3 cells, indicating that VEGF
factor promoted the differentiation of epithelial lineage
from multilineage progenitor cells.
Construction of VEGF and HO-1 genetically
modiﬁed EPCs. EPCs transfected with pCMV-Tag 2B/
VEGFA or pCMV-Tag 2B/HO-1 were examined under
ﬂuorescence microscope. As shown in Fig 3, A, the trans-
fection efﬁciency was roughly 80% for both genes 48 hours
after transfection.ThemRNAlevels andproteinexpressionsofVEGFA andHO-1were detected. As shown in Fig 3, B, basal
level of VEGFA and HO-1 were expressed in nontransfected
EPCs, whereas robust expressions of either VEGFA or HO-1
in EPCs were observed after transfection (P < .001).
Efﬁciency of EPC transplantation rat model of hind
limb ischemia
Incorporation of transplanted EPC in neo-
vasculature. EPCs labeledwithBrdUwere injected into the
animals right after surgery. BrdU IHC staining was per-
formed at days 7 and 14 after operation. Transplanted
EPCswere identiﬁed in tissue sections as brown cells forming
lines (Supplementary Fig 2, online only), indicating such
EPCs survived in the ischemic tissue and were successfully
incorporated in the microvasculature of the ischemic limb.
Transgene expression after transplantation of gene-
modiﬁed EPCs. Expressions of mRNA and protein of
VEGFA and HO-1 in ischemic tissue from the affected
limb were detected with Q-PCR and Western blotting.
VEGFA mRNA and protein expressions in groups VEGF
and VEGFþHO-1 were signiﬁcantly increased, compared
with groups PBS, EPC, and HO-1 (P < .001), whereas no
statistical difference was found between these two groups.
Though less dramatic, a signiﬁcant increase of VEGFA
gene expression was found in group HO-1, compared with
groups PBS and EPC (P < .05) (Fig 4, A, left panel).
Similarly, HO-1 mRNA and protein expressions in group
HO-1 and VEGFþHO-1 were signiﬁcantly increased,
compared with groups PBS, EPC, and VEGF (P <.001),
whereas there was no statistical difference between these
two groups (Fig 4, A, right panel).
Functional assessments of animals after transplantation
MVD quantiﬁcation. MVD is one of the indicators of
revascularization in ischemic tissue. Six animals from each
Fig 2. Endothelial progenitor cell (EPC) biomarkers expression in P3 cells. P3 cells at the end of the 7-day culture were
collected and subjected to EPC biomarkers testing. CD133 and CD34 expressions were quantiﬁed as the percentage of
cells labeled by ﬂuorescein isothiocyanate (FITC)-conjugated secondary antibodies, which were bound to primary
antibodies against these two proteins, data were expressed as the (mean 6 standard deviation)% of triplicate readings of
each sample in one experiment representative of three performed with similar results (A). At day 7, P3 cells intensively
took up 1,1-dioctadecyl-3,3,30,30-tetramethylindocarbocyanine-labeled acetylated low-density lipoprotein (Dil-Ac-
LDL) (red) and bound to an endothelial-speciﬁc lectin-FITC (green) as revealed by ﬂuorescence microscopy (B).
Quantitative analysis of the percentage of cells positive for Dil-Ac-LDL/lectin dual staining (merge) was performed as
described in the Methods section. Total RNA from P3 cells were ampliﬁed by real-time polymerase chain reaction (RT-
PCR) using speciﬁc vascular endothelial growth factor (VEGF)-R2 and b-actin primers. Data were expressed as the
mean 6 standard deviation of three samples of each group in one experiment representative of three performed with
similar results (C). Whole cell extracts were subjected to Western blotting, testing protein expression of VEGF-R2.
The representative image of three independent experiments was shown. *P < .01 vs no human VEGF induction.
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Skeletal muscle sections taken from the ischemic limb were
subjected to IHC staining for vWF. Microvessels in 10
randomly selected high power (400) ﬁelds in each section
were counted. MVD increased in each group in a time-
dependent manner (Table I, Fig 4, B, left panel). At each
time point, MVD in group EPC was statistically higher than
that in group PBS (P < .05) but lower than that in groups
VEGF, HO-1, or VEGFþHO-1 (P < .05). Meanwhile, no
statistical difference in MVD was found between groups
VEGF andHO-1 at any timepoint.GroupVEGFþHO-1did
not show signiﬁcantly increased MVD until day 14 after
operation (295.56 12.1/m2 vs 201.56 10.9/m2 in VEGF
and216.3611.3/m2 inHO-1;P< .001), and thedifference
remained statistically signiﬁcant at day 21 (3576 14.1/m2),
compared with groups VEGF (253.76 9.9/m2) and HO-1
(255.56 12.5/m2) (P < .001) (Fig 4, B, right panel).
Detection of blood ﬂow by LDPI. Subcutaneous
blood ﬂow rate detected by LDPI is an objective indicatorfor blood ﬂow perfusion. As shown in Fig 5, A and B and
Table II, at day 7 after operation, the overall ratio of
ischemic/normal blood ﬂow decreased in all groups. Group
VEGFþHO-1 showed the highest ratio of ischemic/normal
blood ﬂow at each time point, compared with other groups
(P< .001), while no statistical difference was found between
groups VEGF andHO-1 at any timepoint (Fig 5,A). At day
21, perfusions of affected limbs in group VEGFþHO-1
(85.4% 6 17.8%) were comparable to limbs without
surgery. Meanwhile, the degree of restoration of blood ﬂow
of affected limbs in groups VEGF (51.2% 6 13.2%) and
HO-1 (50.4%6 12.9%) was signiﬁcantly higher than that in
groups EPC (39.9% 6 8.5%) or PBS (28.3% 6 7.8%) (P <
.05). The difference between group EPC and group PBS
was also statistically signiﬁcant at day 21 (P < .001).
Comparison of the degree of ischemia damage
among ﬁve groups. The necrosis occurred as early as 10
days after operation. The position of necrosis (mainly toe,
foot, or crus) was largely dependent on severity of ischemia
Fig 3. Validationofvascular endothelial growthfactorA(VEGFA) andhemeoxygenase-1 (HO-1)gene-modiﬁedendothelial
progenitor cell (EPC). EPCswere examined for transfection efﬁciency by ﬂuorescencemicroscopy 48 hours after transfection
with the gene of interest and EGFP (A). Total RNA from transfected cells were ampliﬁed by real-time polymerase chain
reaction (RT-PCR) using speciﬁc VEGFA, HO-1, and b-actin primers. Data were expressed as the mean6 standard devia-
tion of three samples of each group in one experiment representative of three performed with similar results (B, upper panel).
Whole cell extracts were subjected toWestern blotting, testing protein expression of VEGFA, andHO-1. The representative
image of three independent experiments was shown (B, lower panel). *P < .001 vs pCMV-Tag 2B/empty vector control.
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disarticulations of toe, foot, or the distal one-third of the
crus from the affected limb were observed in all groups
except group VEGFþHO-1, indicating transplantation of
VEGFA- and HO-1-modiﬁed EPC prevented animals from
progression to end-stage CLI. The order of necrosis severity
among groups was PBS > EPC > either VEGF or HO-1 >
VEGFþHO-1, and the order of limb salvage rate (11.1% in
PBS, 50.0% in EPC, 63.6% in VEGF or HO-1, 94.4% in
VEGFþHO-1) was the opposite (Table III; Fig 5, C).
DISCUSSION
The results of this study show that transplantation of
both VEGFA- and HO-1-modiﬁed EPC is superior to
transplantation of either VEGFA-modiﬁed or HO-1-
modiﬁed EPC alone in therapeutic revascularization in
rat hindlimb ischemia model. Our results clearly demon-
strate that the combination therapy signiﬁcantly increase
capillary density, promote restoration of perfusion in
ischemic tissue, and improve limb salvage rate, compared
with the transplantation of either gene-modiﬁed EPCalone. Being a convenient and objective method for nonin-
vasive, repeated, and quantitative estimation for dermal
blood ﬂow, LDPI revealed profound differences in limb
perfusion at day 21 after the induction of ischemia among
different treatment groups.
EPC-based therapy, administered either systemically or
locally, has shown promising results in numerous studies.27
Genetically modiﬁed EPC has been considered useful in
the design of strategies to achieve dual purposes: targeted
delivery of therapeutic genes using EPC as vehicle and
enhancement on the angiogenic properties of EPC by the
expression of therapeutic genes.
VEGFA is the most abundant variant of the VEGF
family. The reasons why we chose this VEGF isoform for
transfection in our study were based on several unique
properties of VEGFA: (1) VEGFA is essential for develop-
mental angiogenesis because VEGFA deﬁcient animals are
embryonic lethal28; (2) VEGFA is a hypoxia/glucose
deprivation-inducible protein that characterizes VEGFA
vs other members of the VEGF family and is upregulated
in tissues with insufﬁcient perfusion29; and (3) VEGFA is
Fig 4. Transgene expressions and microvessel density changes after transplantation. To test the efﬁciency of the
transplantation of gene-modiﬁed endothelial progenitor cells (EPCs), six rats from each group were euthanized at day 7
after transplantation. Muscle tissue from ischemic limb was subjected to total RNA and protein extraction, as described
in the Methods section. Total RNA was ampliﬁed by real-time polymerase chain reaction (RT-PCR) using speciﬁc
vascular endothelial growth factor A (VEGFA), heme oxygenase-1 (HO-1), and b-actin primers. Data were expressed as
the mean6 standard deviation of six samples from each group (A, upper panel). Total protein was subjected to Western
blotting, testing protein expressions of VEGFA and HO-1. The representative image of six blots was shown (A, lower
panel). Microvessel density (MVD) was calculated as described in the Methods section at days 7, 14, and 21 after
surgery (six rats from each group at each timepoint). Data were expressed as the mean6 standard deviation capillaries/m2
(B). MVD changes were compared among different time points in the same treatment group (B, left panel), and among
different treatment groups at the same time point (B, right panel). *P < .05 vs phosphate-buffered saline (PBS);
**P < .05 vs PBS or EPC; ***P < .001 vs PBS, EPC, VEGF, or HO-1.
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sine kinase receptors are selectively expressed on vascular
endothelium.30 Furthermore, our previous study18 clearly
demonstrated in experimental animal model that
VEGFA-modiﬁed EPC could increase MVD, enhance
perfusion in ischemic limb, and improve limb recovery
rate, indicating that systemic administration of VEGFA-
modiﬁed EPC remained as a reliable therapeutic approach
for PAD.
Upregulation of stress-inducible antioxidant proteins
such as HO-1 constitutes a defense system enabling tissuecells to cope with ischemia and reperfusion damage.31 In
our study, Q-PCR and Western blotting revealed that
transplantation of HO-1-modiﬁed EPC led to the upregu-
lation of VEGFA protein. This result was consistent with
previous reports that overexpression of HO-1 mediated
VEGF synthesis upon oxidative stress.16 However, there
was a considerable amount of skeletal muscle cells in our
samples of ischemic tissue for Q-PCR or Western blotting.
Skeletal muscle is also a rich source of VEGFA expression,
especially upon ischemia.32 Because of the anti-apoptotic
property of HO-1 and its recently-revealed effect on
Fig 5. Recovery of perfusion and salvage rate of ischemic limbs after transplantation. Subcutaneous blood ﬂow rate was
detected by laser Doppler imager (LDPI). Calculated perfusion was expressed as the percentage ratio of average blood
ﬂow in the surgical limb to that in the healthy limb. Data were expressed as the (mean 6 standard deviation)% of six
samples of each group (A). *P < .001 vs phosphate-buffered saline (PBS); **P < .05 vs PBS or endothelial progenitor
cell (EPC); ***P < .001 vs PBS, EPC, vascular endothelial growth factor (VEGF), or heme oxygenase-1 (HO-1). The
representative LDPI image set of 18 sets of images with similar results, taken from 18 animals at day 21 after surgery,
was shown (B). The degree of ischemic damage in the affected limb evaluated macroscopically was shown (C).
Table I. Microvessel density (MVD) quantiﬁcation (capillaries/m2)
Group n 7 days 14 days 21 days
PBS 6 63.5 6 2.7 87.3 6 8.5 144.3 6 9.3
EPC 6 112.5 6 3.3 142.7 6 7.2 210.7 6 10.3
VEGF 6 153.7 6 6.5 201.5 6 10.9 253.7 6 9.9
HO-1 6 162.5 6 7.2 216.3 6 11.3 255.5 6 12.5
VEGFþHO-1 6 171.5 6 8.5 295.5 6 12.1 357 6 14.1
EPC, Endothelial progenitor cell; HO-1, heme oxygenase-1; PBS, phosphate-buffered saline; VEGF, vascular endothelial growth factor.
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probably the combined effect of increased VEGFA synthesis
in HO-1-modiﬁed EPC and less apoptotic skeletal muscle
cells. In our study, we conducted transplantation of both
VEGFA- and HO-1-modiﬁed EPC, and demonstrated, for
the ﬁrst time, a cooperative role of both VEGF and HO-1
to promote neovascularization.
Similar with other studies associated with therapeutic
use of EPCs, major hurdles such as cell senescence or
phenotypic change during in vitro expansion, unclear
development stage and purity of EPC even positive for
certain markers of epithelial lineage, lack of targeted
delivery, and uncontrolled expressions of exogenous genes
remained in our research. In addition, there are several
limitations that need to be addressed regarding our study.First, we are not able to answer the question whether the
synergistic effect of HO-1 observed in this study was based
on its anti-oxidant property or its angiogenic property.
Second, VEGF exerts various biologic effects through
activating different pathways by binding to speciﬁc receptor
tyrosine kinases. For example, the activation of PI3K/Akt
pathway or the upregulation of antiapoptotic proteins (eg,
B-cell lymphoma 2 [Bcl-2], X-linked inhibitor of apoptosis
protein [XIAP], or survivin) were reported to mediate the
pro-survival activity of VEGF.33 HO-1 exerts its anti-
inﬂammatory or antioxidant effects partially through its
products CO and biliverdin/bilirubin. The proangiogenic
mechanism of HO-1, though not fully understood, is prob-
ably through the key angiogenic factors, including VEGF,
SDF-1, and the recruitment of EPC to sites of vascular
Table III. Limb salvage rate
Group No. Necrosis
Auto-
disarticulation Recovered
Salvage
rate, %
PBS 18 7 9 2 11.1
EPC 18 3 6 9 50.0
VEGF 18 3 4 11 63.6
HO-1 18 4 3 11 63.6
VEGFþHO-1 18 1 0 17 94.4
EPC,Endothelial progenitor cell;HO-1, heme oxygenase-1; PBS, phosphate-
buffered saline; VEGF, vascular endothelial growth factor.
Table II. Calculated perfusion rate (%)
Group No. 7 days 14 days 21 days
PBS 18 11.4 6 3.4 20.8 6 4.2 28.3 6 7.8
EPC 18 18.5 6 1.8 29.3 6 4.6 39.9 6 8.5
VEGF 18 23.2 6 6.3 34.5 6 4.4 51.2 6 13.2
HO-1 18 23.9 6 3.1 34.2 6 4.5 50.4 6 12.9
VEGFþHO-1 18 47.5 6 6.3 59.7 6 8.3 85.4 6 17.8
EPC,Endothelial progenitor cell;HO-1, heme oxygenase-1; PBS, phosphate-
buffered saline; VEGF, vascular endothelial growth factor.
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the downstream pathways or mediators under coexpression
of VEGFA and HO-1.
It is our goal to be able to reveal the detailed molecular
mechanism underlying the synergistic angiogenesis by
VEGFA- and HO-1-modiﬁed EPCs in a future study.CONCLUSIONS
We have shown for the ﬁrst time in rat hindlimb
ischemia model that VEGFA-modiﬁed EPC and HO-1-
modiﬁed EPC synergized with each other in promoting
angiogenesis. The hindlimb ischemia model with LDPI
analysis is an excellent system for assessing candidates of
gene- or cell-based revascularization therapeutics. In addi-
tion to VEGF, the introduction of HO-1 in EPC-based
transplantation may serve as a novel and useful therapeutic
strategy for ischemic disease of lower extremity.
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Western blotting detection of VEGF-R2, VEGF,
and HO-1 protein. Cells were lysed in lysis buffer contain-
ing 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.5 mM
ethylenediaminetetraacetic acid, 0.5% Nonidet P-40, freshly
added 1 mM phenylmethylsulfonyl ﬂuoride, 1 mM
Na3VO4, and 1 protease inhibitor cocktail (Roche,
Indianapolis, Ind). Ischemic muscle tissues were snap-
frozen, grounded in liquid nitrogen and resolved in 2 ml
of ice-cold buffer containing 20 mM Tris-HCl, pH 7.5,
10 mM b-glycerol phosphate, 2 mM sodium pyrophosphate,
1 mM ethylenediaminetetraacetic acid, 1 mM sodium
ﬂuoride, 1 mM phenylmethylsulfonyl ﬂuoride, 1 g/mL leu-
peptin, and 1 mM dithiothreitol. The mixture was homoge-
nized by sonication on ice. Equal amount of protein was
subjected to sodium dodecyl sulfate-polyacrylamide gel
electrophoresis and subsequent transfer to polyvinylidene
ﬂuoride membrane. Blots were incubated overnight at 4C
with rabbit polyclonal antibody against rat VEGF-R2 (sc-
315; Santa Cruz, Dallas, Tex), VEGF (clone 147, sc-507;
Santa Cruz), and HO-1 (clone H-105, sc-10789; Santa
Cruz), followed by the incubation of horseradish peroxidase
conjugated secondary antibodies (Pierce, Rockford, Ill) and
chemiluminescent detection (Roche).
RNA extraction and real-time Q-PCR. Total RNA
was extracted from cells or tissues using Trizol reagent
(Invitrogen). For Q-PCR, 1 mg of DNase-treated total
RNA was reverse transcribed using Superscript II reverse
transcriptase (Invitrogen), and PCR ampliﬁcation was
performed on an ABI PRISM 7700 sequence detection
system (Applied Biosystems, Carlsbad, Calif) using SYBR
green I dye (#4309155; Applied Biosystems) assay chem-
istry. The cycling conditions were as follows: (1) 96C, 10
minutes, one cycle; (2) 95C, 10 seconds / 60C, 1
minute, 40 cycles; and (3) 95C, 15 seconds/ 60 C, 20
seconds / 95C, 15 seconds, one cycle. For normaliza-
tion, we used b-actin as reference gene.
Identiﬁcation of rat bone marrow-derived EPC. P3
EPCs were incubated with 2.4mg/mL 1,1-dioctadecyl-
3,3,30,30-tetramethylindocarbocyanineelabeled acetylated
low-density lipoprotein (Dil-Ac-LDL) (L3484; Invitrogen)
for 1 hour and counterstained with FITC-labeled lectin
from Ulex europaeus (UEA-1-lectin, L9006; Sigma,St. Louis, Mo). Cells were then examined under Nikon
eclipse TE300 ﬂuorescent microscope (Nikon Instruments
Inc, Melville, NY). Cells presenting double-positive ﬂuo-
rescence were considered to be EPC.
EPCs cultured in medium with or without the presence
of human VEGF were stained with anti-CD34 (ICO115;
Santa Cruz Biotechnology, 1 mg per 106 cells) and anti-
CD133 (PAB12663; Abnova, Taipei city, Taiwan; 10-20
mg per 106 cells), followed by incubation with secondary
antibodies conjugated to FITC (Santa Cruz). Samples
were subjected to ﬂow cytometry (FACScar, ELITE-ESP;
Beckman-Coulter, Palo Alto, Calif) analysis for total
number and percentage of positively labeled cells (excita-
tion wavelength [Ex] ¼ 488 nm; emission wavelength
[Em] ¼ 530 nm).
EPCs crawling microscopic slides of logarithmic
growth were collected and ﬁxed with 4% paraformaldehyde
for 30 minutes, followed by PBS washing. IHC detection
was achieved using anti-Rabbit/Mouse Poly-HRP IHC
Detection Kit (2774; Millipore, Billerica, Mass). Rabbit
polyclonal CD34 antibody (250591; Abbiotec, San Diego,
Calf; 1:100), CD133 antibody (C9493; Sigma, 1:100),
and vWF antibody (251228; Abbiotec; 1:100) were used
as primary antibodies. After incubation with anti-Rabbit
Poly-HRP, slides were incubated with freshly prepared
DAB chromogen-buffer solution, followed by hematoxylin
nuclear counterstaining. Negative control slides were run
without primary antibody.
Rat hindlimb ischemia model establishment.1
Brieﬂy, a skin incision was performed on the medial
aspect of the indexed thigh. The femoral artery was
ligated and cut immediately distal to the inguinal liga-
ment and proximal to the popliteal bifurcation site. No
branches were ligated along the length of the excised
segment.REFERENCE
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Supplementary Fig 1 (online only). Morphologic changes of endothelial progenitor cell (EPC). EPCs initially iso-
lated (passage 1, P1) were small, round, and undistinguishable from blood cells (A). P2 cells were more adherent and
changed to spindle shape with a tendency to form cluster or colony (B). P3 cells displayed uniformly spindle-shaped
with long, dendritic-like protrusions and a tendency to form lines (C).
Supplementary Fig 2 (online only). BrdU immunohistochemical staining of muscle tissue from ischemic limb.
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